Molecule

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Friday, December 2, 2022

Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In-person and virtual meetings may be scheduled directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

NUROSENE BUSINESS UPDATE

Retrieved on: 
Thursday, December 1, 2022

TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.

Key Points: 
  • TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.
  • The opportunity At Nurosene, we believe there is a significant opportunity to address the very low rate of success in the clinical trial process, by using the NetraAI technology.
  • Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
  • New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Thursday, December 1, 2022

Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.

Key Points: 
  • Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.
  • CT1812 is an experimental oral sigma-2 (-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
  • The proteomic analyses from our clinical studies in neurodegenerative disease were instrumental in identifying dry AMD as an indication of interest, explained Mary Hamby, Ph.D. , VP of biology at Cognition Therapeutics.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results

Retrieved on: 
Monday, November 28, 2022

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.
  • The company is hosting a conference call today, November 28, 2022, at 4:30 p.m.
  • ET to discuss the results.
  • Presented interim data on the cardiometabolic pipeline in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022 and at a virtual analyst and investor event.

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, November 23, 2022

Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs.

Key Points: 
  • Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs.
  • One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

CURE Media Group announces 2022 Multiple Myeloma Heroes®

Retrieved on: 
Thursday, November 17, 2022

CRANBURY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients, survivors and caregivers, today announced the winners of the 2022 Multiple Myeloma Heroes and Multiple Myeloma Health Equity Heroes award programs.

Key Points: 
  • CRANBURY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients, survivors and caregivers, today announced the winners of the 2022 Multiple Myeloma Heroes and Multiple Myeloma Health Equity Heroes award programs.
  • We are proud to announce the winners of the Multiple Myeloma Heroes and Multiple Myeloma Health Equity Heroes award programs and honor these individuals for their dedication and contributions to make a meaningful difference in the lives of every patient.
  • The 2022 Multiple Myeloma Heroes program recognizes individuals who have demonstrated significant impact in improving the lives of those affected by MM.
  • He has since participated in many fundraising activities for the Multiple Myeloma Research Foundation such as 5Ks and Moving Mountains for Multiple Myeloma.

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

Retrieved on: 
Monday, November 14, 2022

4D Molecular Therapeutics will host a conference call today, Monday November 14, 2022 at 8:00 AM E.T.

Key Points: 
  • 4D Molecular Therapeutics will host a conference call today, Monday November 14, 2022 at 8:00 AM E.T.
  • This clinical data on 4D-150 marks an important milestone for 4DMT, said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • We are developing 4D-150 for the treatment of large and sustainable markets in ophthalmology, including wet AMD and diabetic macular edema.
  • I am looking forward to enrolling patients in the randomized Phase 2 expansion stage of this clinical trial.

Games Industry Veterans and Former FA CEO Unite to Lead New Football-focused Studio, Formation Games

Retrieved on: 
Thursday, November 24, 2022

Alex, Jonty and Neils experience across the world of gaming and football will be pivotal in the development of Formation Games upcoming football ownership game CLUB.

Key Points: 
  • Alex, Jonty and Neils experience across the world of gaming and football will be pivotal in the development of Formation Games upcoming football ownership game CLUB.
  • CLUBs founders, Guy Rogers, Chris Cragg, Tom Russell, Adam McIntee & Mike Burrows join Formation Games team to deepen its broad appeal to football fans globally.
  • CEO Jonty Barnes is a games industry veteran of 33 years and former General Manager of Bungies Destiny franchise.
  • Alex Horne, Formation Games Chair said I know first-hand from my time at the FA the highs and lows that accompany football ownership.

Clinical Trial Supplies Global Market Report 2022: Increasing R&D Expenditure of Pharmaceutical and Biotechnology Companies to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022

The Global Clinical Trial Supplies market is projected to reach USD 5.7 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 9.7% during the forecast period of 2022 to 2027.

Key Points: 
  • The Global Clinical Trial Supplies market is projected to reach USD 5.7 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 9.7% during the forecast period of 2022 to 2027.
  • Factors such a as globalization of clinical trials and growing R&D expenditure in pharmaceutical and biopharmaceutical companies are driving the market.
  • The logistics and distribution segment accounted for the highest growth rate in the clinical trial supplies market, by service, during the forecast period
    In 2021, the logistics & distribution services segment accounted for the largest share of the clinical trial supplies market.
  • On the basis of region, the clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Rest of world.

$1 Billion Worldwide High Throughput Process Development Industry to 2027 - Featuring BMG Labtech, Charles River Laboratories, Corning and Danaher Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022

The report presents a detailed Ansoff matrix analysis for the Global High Throughput Process Development Market.

Key Points: 
  • The report presents a detailed Ansoff matrix analysis for the Global High Throughput Process Development Market.
  • The analyst analyses the Global High Throughput Process Development Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global High Throughput Process Development Market.
  • The Global High Throughput Process Development Market is segmented based on Product & Service, Molecule Type, Technology, End User, and Geography.